EUVIMEDEUVIMED entdecken
Open Access

Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers

Kevin A Reininger iD, Guillaume Onyeaghala iD, Teresa Anderson-Haag iD, David S Schladt iD, Baolin Wu iD, Weihua Guan iD, Casey R Dorr iD, Rory P Remmel iD, Roslyn Mannon iD, Arthur J Matas iD, William S Oetting iD, Paul Stahler iD und 2 weitere

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Kevin A Reininger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hennepin County Medical Center, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney transplant recipients carrying the CYP3A5*1 allele have lower tacrolimus troughs, and higher dose requirements compared to those with the CYP3A5*3/*3 genotype. However, data on the effect of CYP3A5 alleles on post‐transplant tacrolimus management are lacking. The effect of CYP3A5 metabolism phenotypes on the number of tacrolimus dose adjustments and troughs in the first 6 months post‐transplant was evaluated in 78 recipients (64% Caucasians). Time to first therapeutic concentration, percentage of time in therapeutic range (TTR), and estimated glomerular filtration rate (eGFR) were also evaluated. Fifty‐five kidney transplant recipients were CYP3A5 poor metabolizers (PM), 17 were intermediate metabolizers (IM), and 6 were extensive metabolizers (EM). Compared to PMs, EMs/IMs had significantly more dose adjustments (6.1 vs. 8.1, p = .015). Overall, 33.82% of trough measurements resulted in a dose change. There was no difference in the number of tacrolimus trough measurements between PMs and EM/IMs. The total daily tacrolimus dose requirements were higher in EMs and IMs compared to PMs (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusKidney TransplantationHumansImmunosuppressive AgentsCytochrome P-450 CYP3AGenotypeTransplant RecipientsPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

CYP3A5clinical managementkidney transplantstacrolimus

Substanzen

TacrolimusImmunosuppressive AgentsCytochrome P-450 CYP3ACYP3A5 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
  • Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
  • Division of Nephrology, Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Nephrology, University of Nebraska, Omaha, Nebraska, USA.

ORCID-Profile: Kevin A Reininger, Guillaume Onyeaghala, Teresa Anderson-Haag, David S Schladt, Baolin Wu, Weihua Guan, Casey R Dorr, Rory P Remmel, Roslyn Mannon, Arthur J Matas, William S Oetting, Paul Stahler, Ajay K Israni, Pamala A Jacobson

Förderung

  • NIAID NIH HHS

Zitieren

APA

Reininger, K. A., Onyeaghala, G., Anderson-Haag, T., Schladt, D. S., Wu, B., Guan, W., Dorr, C. R., Remmel, R. P., Mannon, R., Matas, A. J., Oetting, W. S., Stahler, P., Israni, A. K., & Jacobson, P. A. (2023). Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers. Clinical Transplantation. https://doi.org/10.1111/ctr.14893

Vancouver

Reininger KA, Onyeaghala G, Anderson-Haag T, Schladt DS, Wu B, Guan W, et al. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers. Clinical Transplantation. 2023. doi:10.1111/ctr.14893

BibTeX
@article{Reininger2023,
  author = {Reininger, Kevin A and Onyeaghala, Guillaume and Anderson-Haag, Teresa and Schladt, David S and Wu, Baolin and Guan, Weihua and Dorr, Casey R and Remmel, Rory P and Mannon, Roslyn and Matas, Arthur J and Oetting, William S and Stahler, Paul and Israni, Ajay K and Jacobson, Pamala A},
  title = {Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14893}
}
Kostenlos starten →